Yale University-Mayo Clinic CERSI

2017-2018 CERSI Scholars

Yale University

Sanket S. Dhruva, MD

Postdoctoral Fellow, Robert Wood Johnson Foundation Clinical Scholars Program, Department of Internal Medicine, Yale School of Medicine
Project Title: Post-Market Surveillance with a Novel mHealth Platform

Dr. Dhruva is a board-certified general cardiologist and Robert Wood Johnson Foundation Clinical Scholar at Yale University School of Medicine. His research interests focus on technology assessment, particularly ensuring that therapies employed in clinical practice are targeted to patients who may benefit. He has studied Food & Drug Administration (FDA) approval decisions for high-risk medical devices, Centers for Medicare & Medicaid Services (CMS) national coverage determinations, and Medicare Part D formulary coverage decisions. Dr. Dhruva has a track record of generating research findings that inform evidence development for high-value care and translating them into meaningful, policy-relevant contributions that also make a mark in the scientific literature.

Ravi Gupta, MD

Doctorate of Medicine Graduate 2017, Yale School of Medicine
Project Title: Evergreening Strategies in U.S. Pharmaceutical Markets: Protecting Profits by Thwarting Generic Competition

Dr. Gupta is a recent graduate of the Yale School of Medicine with an interest in FDA regulation and pharmaceutical policy. His most recent research experience has focused on uncovering barriers in access to medications for patients, including generic availability and drug pricing. He has worked as a Research Assistant for the MIT Jameel Poverty Action Lab in India on rigorous evaluations of health and education development programs. He has also worked with the Centers for Medicare and Medicaid Innovation on designing and implementing state delivery and payment models. Dr. Gupta has gained strong domestic and international research experience from his work in India, Switzerland, Bhutan, and the United States.

Jeremy O’Connor, MD

Postdoctoral Fellow, National Clinician Scholars Program, Yale University School of Medicine
Project Title: Adoption of Immunotherapy Following FDA Approvals: Insights from the Use of Checkpoint Inhibitors

Dr. O’Connor is a general internist who is committed to a career that advances health equity for patients with cancer. He became interested in health equity during residency, and is pursuing postgraduate training in health services research. His previous work has focused on financial toxicity in cancer treatment, as well as the relation between social isolation and cost-coping strategies among patients with cancer. Because health policy has an important role in rising costs of care, as well as in the equity of care that is delivered to patients, he became interested in work that focuses on the intersection of health policy, access to care, and socioeconomic disparities in cancer outcomes. In addition, he became interested in the role of structural and regulatory processes in the perpetuation of racial disparities in cancer treatment. After fellowship, Dr. O’Connor hopes to work as a clinician-investigator who generates policy-relevant research that informs efforts to reduce barriers to care among vulnerable populations.

Anand D. Gopal, BA, BS

Doctorate of Medicine Candidate (2018), Yale School of Medicine
Project Title: Characteristics of Clinical Studies of Off-Label Indications for Novel FDA-Approved Therapeutics in Ophthalmology

Anand is a current MD candidate at the Yale School of Medicine and an aspiring ophthalmologist whose academic interests rest at the intersection of meta-research and policy. He hopes to shed light on avenues through which research and regulation may better align to serve clinical decision-making and patient care. He is specifically interested in issues pertaining to integrity and transparency in clinical research and the implications that these issues have on evidence quality. As a rising clinician, Anand has a vested interested in ensuring that clinical practice is driven by the highest standards of unbiased evidence.

Mayo Clinic

Ali Duarte-Garcia, MD

Rheumatology Fellow, Mayo Clinic
Project Title: Clinical Uptake, Utilization Patterns and Safety of Belimumab and Rituximab in Systemic Lupus Erythematosus

Dr. Duarte-Garcia is a Rheumatology Fellow at the Mayo Clinic focusing on comparative effectiveness of biologic medications in multiple inflammatory arthritides. Dr. Duarte-Garcia plans to identify the best practices to deliver rheumatologic care that are efficient, safe, and cost effective.

Joseph A. Gottwald, PharmD

Doctorate of Medicine Candidate (2020), Mayo Clinic School of Medicine
Project Title: Effect of Sodium Channel Blocking Antiepileptic Drugs on Electrocardiogram Markers of Sudden Cardiac Death in Epilepsy

Dr. Gottwald is a graduate of the Doctor of Pharmacy program at Albany College of Pharmacy and Health Sciences. As an MD Candidate at Mayo Clinic School of Medicine, he hopes to integrate a focus on pharmacotherapy into his future practice. His current research aims to develop improved predictive models and preventative strategies for patients at high risk of cardiac arrhythmias and sudden death, with a particular focus on patients with epilepsy.

Yanina Natanzon, PhD, MS

Postdoctoral Research Fellow, Mayo Clinic
Project Title: Germline Genetic Variation Effect on Second-Line Drug Efficacy in Epithelial Ovarian Cancer

Dr. Natanzon is a Postdoctoral Research Fellow in the field of Cancer Genetic Epidemiology. During her undergraduate training, she collected and evaluated prospective epidemiological data for a CDC-funded project as part of the San Francisco Department of Public Health Tuberculosis Control Division. She has further built upon this knowledge during her doctoral work in genetic epidemiology, during which time she collaborated with a large multi-ethnic women’s cohort study and designed a project utilizing repeated measures modeling to evaluate how genetic variation affects complex traits over time. She has also tackled methodological difficulties by applying multivariate analysis and data reduction techniques to real-world multi-omic datasets, and computational approaches to solve these problems. Dr. Natanzon has been immersed in learning all aspects of ovarian cancer etiology and treatment in her postdoctoral training at Mayo. Prior to her doctoral program, she completed a Master’s degree in applied anatomy which included in-depth study of the four anatomical sciences. Her long-term research interests lie in how the utilization of pharmacogenomics data, incorporated into the FDA regulatory guidelines, can aid optimization and repurposing of currently available drugs to improve survival in rare and recalcitrant cancers.

Liwei Wang, MD, PhD

Research Fellow of Medical Informatics, Mayo Clinic
Project Title: Combining Electronic Medical Records with Spontaneous Reports in Discovering Adverse Drug Events: A Case Study of Conventional DMARDs for Rheumatoid Arthritis

Dr. Wang’s current work is centered on drug knowledge discovery, based on various data sources such as Electronic Medical Records (EMRs), drug package inserts, and the FDA Adverse Event Reporting System (FAERS). She has medical informatics training and research experience in ontology and Natural Language Processing (NLP) as well as medical sciences. Previously Dr. Wang has leveraged NLP methods to normalize FAERS and produced a freely accessible knowledge-enhanced data mining set, i.e., AERS-DM. After joining the Mayo Clinic, she worked on a U24 project and compared three information sources for smoking information, including narrative text of clinical notes, patient-provided information, and diagnosis codes in EMRs. In terms of academic service, she has helped organize AMIA iHealth 2016 Pre-Conference Workshops, Innovative Informatics and Analytics in Medicine, and the 2014 Workshop on Translational Biomedical and Clinical Informatics in conjunction with the 8th International Conference on Systems Biology and the 4th Translational Bioinformatics Conference (ISB/TBC 2014).